Cartesian Therapeutics, Inc. (RNAC)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Cartesian Therapeutics, Inc. reported revenue of $400.0K, down 99.0% from the prior year. The company ran a net loss, with a net margin of -32575.5%. It held $296.41M in total assets against $422.65M in total liabilities.
Key ratios (FY2025)
-35851.2%
Operating margin
-32575.5%
Net margin
-99.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $400.0K | $38.27M | $26.00M | $110.78M | $85.08M | $16.60M | $6.68M | $903.0K | $207.0K | — |
| Operating Income | -$143.41M | -$43.90M | -$86.42M | $14.54M | -$4.60M | -$56.82M | -$52.45M | -$65.02M | -$63.78M | -$34.67M |
| Net Income | -$130.30M | -$77.42M | -$219.71M | $35.38M | -$25.69M | -$68.88M | -$55.35M | -$65.34M | -$65.32M | -$36.21M |
| EPS (Diluted) | $-5.02 | $-4.49 | $-49.76 | $0.10 | $-0.22 | $-0.68 | $-1.22 | — | — | — |
| Total Assets | $296.41M | $435.02M | $305.05M | $165.89M | $159.88M | $165.44M | $99.57M | $44.48M | — | $89.30M |
| Total Liabilities | $422.65M | $441.82M | $444.68M | $72.06M | $137.36M | $183.44M | $91.17M | $49.90M | — | $34.34M |
| Shareholders' Equity | -$126.24M | -$6.80M | -$440.18M | $93.83M | $22.52M | -$18.01M | $8.40M | -$5.42M | $51.81M | $54.96M |
| Cash & Equivalents | $125.14M | $212.61M | $76.91M | $106.44M | $114.06M | $138.69M | $89.89M | $37.40M | $70.62M | $58.66M |
| Operating Cash Flow | -$73.94M | -$23.67M | -$51.16M | -$31.63M | -$60.38M | $34.88M | -$51.44M | -$59.16M | -$52.03M | — |
| Capital Expenditures | $5.45M | $9.09M | $206.0K | $1.20M | $1.08M | $815.0K | $47.0K | $884.0K | $733.0K | $586.0K |
| Shares Outstanding | 26.01M | 25.77M | 5.40M | 153.04M | 123.62M | 108.07M | 86.33M | 22.47M | — | 18.44M |